Soriot told the Andrew Marr show today: "We are confident the vaccine will work". A Chinese company created a similar shot. But there were no serious side effects, researchers reported in the journal Lancet.
To assess whether the vaccine works, statisticians will compare the number of infections in the control group with the number of infections in the vaccinated group. It will also involve 500 adults, including participants older than age 60.
Naming the Indian firms working on vaccines for COVID-19, Gagandeep Kang, executive director of the Translational Health Science and Technology Institute, Faridabad, had said last month that while Zydus Cadila is working on two vaccines, Serum Institute, Biological E, Bharat Biotech, Indian Immunologicals, and Mynvax are developing one vaccine each.
The researchers, who use cellphone data to predict the epidemic's course and monitor social mobility, said most American communities should not experience a second wave of rising Covid-19 cases if they continue to maintain social distancing as nonessential businesses reopen and other restrictions meant to curb the new coronavirus' spread are lifted.
"We're in the freakish position of wanting Covid to stay, at least for a little while".
Just days ago, scientists leading the University of Oxford's coronavirus vaccine development expressed optimism about their progress - more than 1,000 people in the United Kingdom have been inoculated already, and 10,000 more will be given the vaccine in May and June.
CanSino is awaiting results from 500 volunteers injected in a next-step study. Pollard noted that people over 70 often don't get as much protection from vaccines as younger people.
"If transmission remains high, we may get enough data in a couple of months to see if the vaccine works, but if transmission levels drop, this could take up to six months", the university said in a statement. But he cautioned the shot's effectiveness still is unclear, citing the monkey research. Question is whether it will completely clear the virus or stop patients from being sick. Numerous candidates work in different ways, and are made with different technologies, increasing the odds that at least one approach might succeed.
The company has promised to produce at least 400 million doses and secured total manufacturing capacity to produce 1 billion doses by the end of 2021.
It's a huge gamble that could waste a lot of money if their choices fail and must be thrown away.
'And there's no doubt, starting in September, we will start delivering these doses of vaccine to the British Government for vaccination'.